Mondego Bio
Cantanhede
About Mondego Bio
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2025)
- Website: mondegobio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/mondego-bio-2219516 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.